Gene therapy may reduce infusions for pompe patients

NCT ID NCT04174105

First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 30 times

Summary

This study tests a new gene therapy called AT845 for adults with late-onset Pompe disease. The goal is to see if a single dose can help the body produce the missing enzyme, potentially reducing or replacing the need for regular enzyme infusions. Eleven participants will receive one of several doses and be monitored for safety and muscle improvements.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POMPE DISEASE (LATE-ONSET) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Newcastle Upon Tyne Hospitals Foundation Trust Clinical Research Facility

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • Stanford University

    Palo Alto, California, 94304, United States

  • University of California Irvine, Department of Neurology

    Orange, California, 92868, United States

  • University of Utah, Division of Medical Genetics

    Salt Lake City, Utah, 84108, United States

Conditions

Explore the condition pages connected to this study.